Healthcare
SQZ Biotechnologies Company(SQZB)
Live Price
Offline$0.024
+0.00% today
1Y Change
-14.29%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- -22.4%
- EPS Growth
- -10.8%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SQZ Biotechnologies Company (SQZB) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 14.3% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -22.4%, EPS growth of -10.8%, a dividend yield of 0.0%. What stands out right now is revenue -22.4%, EPS -10.8%, free cash flow -1.6% with operating margin -383.7% and ROIC -81.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SQZB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-22.4% vs +7.6% peer median
Operating Margin
Below sector median
-383.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -22.4% and EPS is at -10.8%, with operating margin around -383.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 26, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Jun 4, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SQZB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SQZB Max Drawdown
-23.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SQZB and SPY.
Company Overview
SQZ Biotechnologies Company
Other OTC
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
- Leadership
- Lawrence J. Knopf
- IPO Date
- Oct 30, 2020
- Employees
- 53
- Street Address
- 200 Arsenal Yards Boulevard
- Mailing
- Watertown, MA, 02472
- Region
- Watertown, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 758 8672
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.4
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- -22.4%
- EPS
- -10.8%
- Free Cash Flow
- -1.6%
Profitability
- Gross Margin
- 46.6%
- Operating Margin
- -383.7%
- Net Margin
- -377.9%
- ROE
- -87.7%
- ROIC
- -81.7%
Balance Sheet
- Debt/Equity
- 0.60
- Current Ratio
- 3.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.